SYN-TECH Chem. & Pharm. Co., Ltd.

TPEX:1777 Stock Report

Market Cap: NT$4.1b

SYN-TECH Chem. & Pharm Past Earnings Performance

Past criteria checks 4/6

SYN-TECH Chem. & Pharm has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 3.9% per year. SYN-TECH Chem. & Pharm's return on equity is 13.3%, and it has net margins of 26.9%.

Key information

13.9%

Earnings growth rate

3.1%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate3.9%
Return on equity13.3%
Net Margin26.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More Debt

Mar 19
SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More Debt

Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Feb 26
Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?

Feb 05
Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?

SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their Shares

Jan 10
SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their Shares

SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather Sparingly

Dec 19
SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather Sparingly

Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Nov 28
Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield

Revenue & Expenses Breakdown

How SYN-TECH Chem. & Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:1777 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,2153279241
30 Jun 241,2153049142
31 Mar 241,1172739038
31 Dec 231,1152519038
30 Sep 231,0912499339
30 Jun 231,0422709140
31 Mar 231,0583069040
31 Dec 229862959040
30 Sep 228833188239
30 Jun 227812307836
31 Mar 228541808539
31 Dec 218931778636
30 Sep 219721668633
30 Jun 211,0121758832
31 Mar 219841928027
31 Dec 209841878227
30 Sep 201,0281838426
30 Jun 201,0812058426
31 Mar 209871668327
31 Dec 199461597827
30 Sep 198821677628
30 Jun 197951397528
31 Mar 197881687428
31 Dec 187851547329
30 Sep 187291306727
30 Jun 186991116628
31 Mar 18701836628
31 Dec 17695606830
30 Sep 17737857335
30 Jun 177471007535
31 Mar 177421127835
31 Dec 167671587634
30 Sep 167581617331
30 Jun 167681896830
31 Mar 167271666228
31 Dec 156841566027
30 Sep 156511545826
30 Jun 156321385925
31 Mar 156241385825
31 Dec 146091285825
30 Sep 145791085524
30 Jun 14536845023
31 Mar 14528805023

Quality Earnings: 1777 has a large one-off gain of NT$68.6M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 1777's current net profit margins (26.9%) are higher than last year (22.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1777's earnings have grown by 13.9% per year over the past 5 years.

Accelerating Growth: 1777's earnings growth over the past year (31.6%) exceeds its 5-year average (13.9% per year).

Earnings vs Industry: 1777 earnings growth over the past year (31.6%) exceeded the Pharmaceuticals industry 11.9%.

Return on Equity

High ROE: 1777's Return on Equity (13.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 16:04
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SYN-TECH Chem. & Pharm. Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Regina LeeIBTS Investment Consulting Co., Ltd.
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.